Ashita Dhillon
Ph.D., Six Sigma, RAC
Hire this person
Send a job offer directly to this candidate
About
CMC scientist passionate about drugs development and public health. Collaboration with colleagues on CMC strategy for successful outcomes for clinical trials, marketing applications, risk assessments and complex post approval changes for supply continuity. Utilizie scientific, process improvement and regulatory experience to ensure product quality, compliance and innovation.
High adaptability to biologic modalities and novel science based new drug discovery platforms. 12 years in CMC Global Regulatory Affairs (commercial post approval and development Phase1/2, Phase 3 studies including BLA/NDA submission) across diverse modalities Biologics- recombinant DNA proteins ADC, mAb, CGT (live cells, AAV), SM/Oligonucleotide/peptide including device; 5 years Quality Assurance i.e Clinical Research, GCP, Clinical and Commercial Drug Manufacturing CGMP; 12 years Biologics R&D (genomics, sequencing, molecular biology, cell biology/cell banks, plasmids; protein fermentation enzymes, purification and protein biochemistry
Experience
Global Regulatory Affairs CMC (Consultant) - Takeda Pharmaceuticals
(2025-05 - 2026-04)
Supporting Neurology and Oncology programs- Small Molecule
- NDA activities-Providing support for M3 review in Mediva, change controls, risk assessments, briefing book authoring strategy (Type C), leading PACMP for site changes post NDA submission
- IMPD activities-Providing support for activities like EU CTR RTQ
- Interim lead for Oncology program in Marketed Products
- Created Protocol for Dossier gap analysis, led India MAA and Marketed Product Playbook, Change Controls support
Lead Candidate for Director Reg CMC Role - Moderna - Norwood, MA
(2025-03 - 2025-04)
Rare disease - Waited for the offer and position was eliminated June 2025
Director Regulatory CMC Strategy - PepGen - Boston, MA
(2024-04 - 2025-02)
Antisense Oligonucleotide Platform, Rare Neuromuscular disorder Phase 1/2. Position impacted by agency feedback on the lead drug Dec. 2024
- Set up a new Regulatory CMC function
- Developed regulatory processes and procedures to support CMC components of Regulatory Submissions and performing gap analysis
- Led preparation of high-quality license applications IND/IMPD specific to CMC content and support with templates
- Supported HA responses UK, Canada, EU-BfArM
- Provided guidance on Regulatory CMC aspects of product development phase including planning HA meetings
- Developed/implemented effective CMC regulatory strategies for Submission e.g IND/CTA/NDA/MAA) and identify regulatory risks
- Provided strategy for EOP 2 meeting, Phase III and NDA, while planning CDMO and technology change
- Provided CMC regulatory guidance to Manufacturing and quality teams, evaluate CMC change controls
- Performed assessments of manufacturing change controls and provide guidance on process improvement
Associate Director Regulatory CMC GRA - Vertex Pharmaceuticals - Boston, MA
(2022-04 - 2024-03)
Regulatory CMC/Lead Strategist for Cell and Gene therapy programs in CGT
- Led the IND authoring for the Gene Therapy program for FIH study, storyboarding within templates, performing regulatory risk assessment, technical reports planning -plasmid design, upstream and downstream from contract manufacturers
- Managed HA meeting-KOM and storyboarding for PEI Germany, FDA Type C
- Supported the Heme program during BLA filing to review gaps
- Supported diabetes program with regulatory strategy for both cells and device and improving CC process
- Supported COE for technology transfer initiatives
- Process improvement in management of Change Controls
- Collaborated with QA, functional team, Clinical RA, project Management
Senior Manager Regulatory CMC GRA - Takeda Pharmaceutical - Cambridge, MA
(2020-06 - 2022-04)
Regulatory CMC strategist/lead for EDG Programs– nanoparticle, enzyme base orals, microbiome, mAb and small molecule
- Led/managed writing, preparation review and approval of regulatory CMC dossier for submission: IND, IND amendments, Annual Reports, FDA meeting requirements Type D (BB/MR), IB, PIP, FDA information request
- Provided interpretation of Regulatory guidance, regulations and directives to product /analytical development group regarding their applicability
- Worked with Regulatory ops, submission management to support development of internal process
- Collaborated with GRA to develop Global CMC Regulatory strategy and risk mitigation
- Identified CMC risks with the technical team, support regulatory compliance with change controls, quality activities audit findings, review RFP, SOW and participate in CDMO selection process
- Participated in HA meeting Type C written response, followed by teleconference on Microbiome project
Manager Regulatory CMC GRA - Takeda Pharmaceutical - Cambridge, MA
(2018-03 - 2020-06)
Reg. CMC Lead for Early development projects / New Modalities
- Led programs in various therapeutic areas GI, Neurology, Oncology
- Member of COE cell banking, bioinformatics
- Worked with the Submission managers on kick off meetings, please review and key project timelines
- Tracked and supporting with annual report, IND Amendments, FDA IR, IND, IMPD, filing the Canada DMF
- Initiated collaboration with VBU for microbiome project on animal derived media and initiating risk assessment
Manager Regulatory Affairs CMC, Medical Development - AMAG - Waltham, MA
(2017-05 - 2018-03)
US based Maternal Health products, DS/DP Small molecule/device Combination products
- Managed Drug Substance and Drug Product CMC submissions updates e.g, Annual reports, CBE-0, CBE-30 and PAS
- Participated in meetings to respond to agency questions for submissions, understand agency responses to Type B meeting Pre sNDA questions
- Provided regulatory assessments of manufacturing changes for CMOs within the change control system and provide filing strategy guidance to Technical Operations and Quality department
- Developed and implement short and long-term regulatory CMC strategies for assigned projects and programs with key partners and stake holders e.g pharmaceutical Development and Technical Operations
- Supported regulatory compliance with respect to filing requirements
Regulatory Associate II Global Regulatory Affairs, CMC Biologics - Sanofi (Genzyme) - MA
(2014-01 - 2017-05)
Global Site CMC support for Fabrazyme, Thyrogen, Cerezyme) Orphan Drug
- Managed and maintained the Quality and regulatory compliance of Fabrazyme/Cerezyme dossier by providing assessments for Deviations and GMP investigations
- Improved the Change Control Process based on Sanofi SOPS and ICH Q12 principles
- Managed the review and assessment of change controls for impact on US and EU regulatory filings and supported GRA by working along RA International colleagues
- Collaborated with cross functional teams-Manufacturing, Analytical, Facilities
- Regulatory CMC person in plant (PIP) for Global Cell banking for multiple products (commercial and development)
- Managed regulatory review and approval of technical documentation i.e. technology transfer protocols (cell banks from development to industrial operations), validation protocols, PV reports, specification development reports
- Managed Mass Biologics Site CMC regulatory tasks: Batch record review, document change review, project specific regulatory support
- Provided CMC Regulatory Strategy and CMC project support (UF/DF, Expanded Roller Bottle, Reprocessing, Harvest extension)
- Collaborated with EU colleagues to review CMC variation documentation to support Submission (EMA) for DCP gap closure
- Supported regulatory submissions (BLA supplements, Annual report, YBPR)
- Collaborated with Japan, EU and Canada on strategy and support Asia Pacific region with submissions
- Supported Dossier Compliance Program using eCTD for US, EU
- Provided support for Health Authority inspections and site related meeting
Principal Compliance Specialist - Genzyme - Allston, MA
(2012-07 - 2013-12)
Commercial DS/DP Mfg CMC Cerezyme) Orphan Drug
- Supported Regulatory Compliance for approved products Site Master File, Inspection Readiness team, audit response
- Provided Health Authority Audit support and managed site
Education
Ph.D. - University of North Carolina (UNC)